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Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF),
and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome symptoms,
which have a significant negative impact on patients’ quality of life. It may also be present in patients with
advanced polycythemia vera (PV) or essential thrombocythemia (ET). Until recently, none of the therapies used to
treat MF were particularly effective in reducing splenomegaly. The discovery of an activating Janus kinase 2 (JAK2)
activating mutation (JAK2V617F) that is present in almost all patients with PV and in about 50-60 % of patients
with ET and PMF led to the initiation of several trials investigating the clinical effectiveness of various JAK2
(or JAK1/JAK2) inhibitors for the treatment of patients with ET, PV, and MF. Some of these trials have documented
significant clinical benefit of JAK inhibitors, particularly in terms of regression of splenomegaly. In November 2011,
the US Food and Drug Administration approved the use of the JAK1- and JAK2-selective inhibitor ruxolitinib for
the treatment of patients with intermediate or high-risk myelofibrosis, including PMF, post-PV MF, and post-ET
MF. This review discusses current therapeutic options for splenomegaly associated with primary or secondary
MF and the treatment potential of the JAK inhibitors in this setting.
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Myelofibrosis (MF) is a clonal stem cell malignancy that
presents clinically with 3 cardinal problems: progressive
anemia, splenomegaly, and chronic incapacitating symp-
toms such as fatigue, bone pain, fever, night sweats, and
weight loss [1]. It is one of 3 Philadelphia chromosome–
negative myeloproliferative neoplasms (MPNs) that share
elements of pathogenesis and symptomatology that may be
related to dysregulated Janus kinase (JAK) signaling [2-4].
The other two are polycythemia vera (PV) and essential
thrombocythemia (ET).
Splenomegaly, resulting from extramedullary hematopoiesis,
accounts for some of the most debilitating symptoms of
MF, whether primary or secondary to PV or ET. It contri-
butes to the morbidity associated with MF by causing* Correspondence: sverstov@mdanderson.org
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distribution, and reproduction in any mediumearly satiety, dysregulated gastrointestinal function, portal
hypertension, decreased physical activity, distressing ab-
dominal pain, and worsening of assorted cytopenias sec-
ondary to splenic sequestration [5]. About 10 % of MF
patients present with severely symptomatic splenomegaly at
diagnosis; another 50 % will develop it within 4 years [6].
The relationship between dysregulated JAK signaling
and the signs and symptoms of MPNs is well estab-
lished [2-4]. The understanding of dysregulated JAK-
STAT (signal transducer and activator of transcription)
activity in MPNs as the basic pathophysiologic abnor-
mality in practically all patients with MPNs has led to the
clinical development of several JAK2 inhibitors. This re-
view will discuss the therapies (apart from bone marrow
transplant) currently used to treat splenomegaly and
splenomegaly-related symptoms in patients with MF
and the potential role of the JAK2 (as well as JAK1/
JAK2) inhibitors.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Surgical therapy
Splenectomy has a long history of providing palliative re-
lief for select patients with symptomatic splenomegaly. Al-
though surgical technique and the availability of specific
surgical expertise have improved, the procedure remains
prone to significant rates of peri- and post-operative mor-
bidity and mortality. Results of a retrospective study of
314 patients with MF-related splenomegaly who under-
went splenectomy at the Mayo Clinic-Rochester between
1976 and 2004 show a perioperative complication rate of
27.7 % and a mortality rate due to surgical complications
of 6.7 % [5]. The median OS after splenectomy was
19 months with 48 %, 50 %, and 40 % of patients ex-
periencing an improvement in splenomegaly-related
symptoms, anemia, and portal hypertension, respect-
ively. No difference in post-splenectomy OS was
noted when analyzed against leukemic transformation,
MF risk score, decade during which splenectomy was
performed, or type of MF.
Patient selection is critical to limiting peri- and post-
operative morbidity. Preoperative thrombocytopenia
with platelets < 50x109/L appears to be associated with
significantly worse OS. Patients with a history or suspi-
cion of splenic infarct may be prone to a higher inci-
dence of postoperative bleeding [5]. Splenectomy is
appropriate only for patients with substantial splenic
symptoms unresponsive to at least 1 prior medical ther-
apy and those with an adequate performance status and
a life expectancy of more than 1 year. Patients should be
in otherwise good health without decompensated coagu-
lopathy or significant comorbidities.
Radiotherapy
Splenic irradiation is used in select patients to control
various debilitating MF-associated symptoms. In general,
the most appropriate candidates are those with signifi-
cant symptoms and an adequate platelet count who, be-
cause of age or comorbidities, are not candidates for
splenectomy [7]. Response rates ranging from 63 % to
95 % have been reported [8,9]. The results are transient,
however, lasting for a median of only 6 months in one
study [8] and 3.5 months in another [9]. The com-
plications, which include myelosuppression, can be se-
vere or even life-threatening. Significant side effects
include potentially critical cytopenias, hemorrhage, com-
plicated post-irradiation splenectomy [8] and delayed
hemorrhage [7].
Recently, 2 cases were reported in which a regimen of
induction-maintenance radiation therapy was used to
treat MF with a marked improvement of the underlying
accelerated phase of the disease [10]. At induction doses
of 100 cGy (in 4 fractions of 25 cGy/fraction) with main-
tenance at the same or higher level, there was completeresolution of peripheral leukoerythroblastosis and eradi-
cation of peripheral blasts in one patient, and significant
reduction in leukoerythroblastosis in the other. Both
patients had marked improvement in functional status
and a reduction in spleen size from >30 cm below the
left costal margin (LCM) to 22 cm and 15 cm. The
authors of this report concluded that this regimen was
well tolerated and should be considered in specific clin-
ical situations (e.g., rapid growth of spleen).
Medical therapy
Prior to the FDA’s approval of ruxolitinib, medical ther-
apies used to treat MF in clinical practice were limited
to hydroxyurea, immunomodulatory drugs, alkylating
agents, hypomethylating agents, and other chemothera-
peutic agents (e.g., cladribine). A comparison of existing
and investigational medical therapies is presented in
Table 1.
Hydroxyurea (HU)
Despite limited efficacy in reducing spleen size [11,12] and
no formal clinical trials to support its use, HU (also known
as hydroxycarbamide) remains the most common first-
line agent used to treat splenomegaly in MF. In a study
evaluating 69 PMF patients [13] treated with HU either
alone (55 %) or in combination with erythropoiesis-
stimulating agents or anagrelide (45 %), a response to HU
as measured by the International Working Group for
Myelofibrosis Research and Treatment (IWG-MRT) cri-
teria [14] was documented in 28 % of patients. Multivari-
ate analysis showed a significant association between
JAK2V617F positivity and response to HU [13]. Another
retrospective study [12] with 40 MF patients treated with
HU reported the following symptom improvements: bone
pain (100 % of patients), constitutional symptoms (82 %),
pruritus (50 %), splenomegaly (40 %), and anemia
(12.5 %). Overall clinical improvement (IWG-MRT) was
observed in 40 % of patients with a median duration of re-
sponse of 13.2 months.
In many patients the long-term benefit from HU treat-
ment is curtailed because of progressive loss of efficacy
and/or development of resistance or intolerance to HU.
Shortcomings of HU treatment include the need for
dose titration, which may be limited by cytopenia and a
relatively long time (2–3 months) to significant benefit,
which is generally not sustained [7].
Immunomodulatory drugs (IMiDs)
Thalidomide (Celgene Corp., Summit, NJ, USA), an
IMiD with antiangiogenic and anti-inflammatory proper-
ties, has shown limited benefit with respect to spleno-
megaly in MF [15,16]. In one study, only 19 % (4/21)
of patients receiving concomitant thalidomide and pred-
nisone therapy achieved splenomegaly reduction ≥ 50 %
Table 1 Comparison of Selected Drugs in Terms of a Response
Agent Splenomegaly1 Anemia2 Symptoms3 References
IMiDs
Thalidomide 19 % 43 % NS [15]
(Celgene Corp., Summit, NJ, USA) 8 % 22 % NR [16]
Lenalidomide 10 % 19 % NR [48]
(Celgene Corp., Summit, NJ, USA) 42 % 30 % NR [18]
Pomalidomide 0 ≤40 % NR [21]
(Celgene Corp., Summit, NJ, USA) 11 % 37 % NR [22]
0 17 % NR [23]
JAK Inhibitors
Ruxolitinib (INCB018424) 44 % 14 % 52–82 % [42]
(Incyte Corporation, Wilmington, DE, USA—US rights;
Novartis AG, Basel, Switzerland—ex-US rights)
42 %4 NR 46 %5 [43]
32 %5 NR NR [44]
SAR302503 (TG101348) (Sanofi, Paris, France) 39 % 0 25–89 % [47]
CYT387 (Cytopia/YM Biosciences, Mississauga, Ontario, Canada) 45 50 % NR [49]
Pacritinib (SB1518) (S*Bio Pte Ltd, Singapore) 44 % <1 % NR [50]
Lestaurtinib (CEP-701) (Cephalon, Frazer, PA, USA) 18 % 1 % NR [51]
mTOR Inhibitor
Everolimus (RAD001) (Novartis AG, Basel, Switzerland) 17 % <1 % 69 %5 [52]
IMiDs = immunomodulatory drugs; NR = not reported; NS = not significant.
1Percentage of patients achieving ≥50 % reduction in spleen size, unless otherwise specified.
2Percentage of patients achieving a ≥2 g/dL increase in Hb, unless otherwise specified.
3Percentage of patients achieving complete resolution of symptoms.
4Percentage of patients achieving ≥35 % reduction in spleen volume.
5Percentage of patients achieving ≥50 % reduction in total symptom score on the Myelofibrosis Symptom Assessment Form.
Randhawa et al. Journal of Hematology & Oncology 2012, 5:43 Page 3 of 7
http://www.jhoonline.org/content/5/1/43vs. baseline [15]. In another study, only 8 % (4/50) of
patients receiving thalidomide-prednisone alone or in
combination with either oral cyclophosphamide or eta-
nercept met the IWG-MRT criteria for clinical improve-
ment of splenomegaly [16].
Lenalidomide (Celgene Corp., Summit, NJ, USA), a
second-generation IMiD, is more potent than thalidomide
and has a different toxicity profile. In a study of 68
patients with MF treated with lenalidomide, 33 % (14/42)
of patients with splenomegaly had a reduction in spleen
size by palpation. Lenalidomide also improved anemia in
22 % of patients [17]. The effect of prednisone on the tol-
erability and response rates of lenalidomide was evaluated
in a phase II trial in 40 patients with MF. After a median
follow-up of 22 months, the overall response rate was
42 % and 30 % for splenomegaly and anemia, respectively
[18]. In a report comparing results with IMiDs in sequen-
tial phase II studies conducted at the M.D. Anderson
Cancer Center, where MF patients received thalido-
mide, lenalidomide, or lenalidomide with prednisone,
the overall response rate was 16 %, 34 %, and 38 %,
respectively (P = 0.06), with a median response dur-
ation of 13, 7, and 34 months (P = 0.042), respectively
[19]. Although experience is limited, in patients with
deletion 5q (del5q; 5q-) chromosomal abnormality,
treatment with lenalidomide can result in complete
hematologic remission, cause resolution of leukoery-
throblastosis, and improve medullary fibrosis. Thus,lenalidomide is recommended as the first-line agent in
such patients [20].
Pomalidomide (Celgene Corp., Summit, NJ, USA) is
the newest IMiD under investigation for use in MF. In a
phase II trial by Tefferi et al., pomalidomide with or
without prednisone had no effect on spleen size [21]. In
a dose-escalation trial, treatment with pomalidomide
resulted in≥ 50 % reduction in palpable spleen size in
11 % (2/19) of patients [22]. The most recent study eval-
uated low-dose (0.5 mg/day) pomalidomide in 58
patients with MF. No reduction in splenomegaly was
seen [23].
Alkylating agents
In a study of low-dose melphalan (2.5 mg 3 times/week
with a possible increment to 2.5 mg daily) Petti et al.
[24] reported a response rate of 66.7 %. Responses in
spleen size reduction, classified as complete clinical re-
sponse (CCR; normalization of spleen size assessed as
palpable organ length below the LCM), partial clinical
response (PCR; ≥ 50 % reduction in spleen length), and
no response (neither CCR nor PCR) were observed in
23 %, 32 %, and 46 % of patients, respectively.
Busulfan has been used to reduce huge splenomegaly
and/or severe leuco-thrombocytosis [25]. However, the
prolonged administration of busulfan [26] or sequential
use of busulfan and hydroxyurea [27] has been asso-
ciated with an increased incidence of leukemic evolution
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cell carcinoma [28].
Hypomethylating agents
The hypomethylating agents, 5-azacytidine (Celgene
Corp., Summit, NJ, USA) and decitabine (Eisai Inc.,
Woodcliff Lake, NJ, USA), are currently under investiga-
tion for use in MF. In a phase II trial evaluating the effi-
cacy of 5-azacitidine in relapsed/refractory or newly
diagnosed MF with poor prognosis, 34 patients received
75 mg/m2 5-azacitidine subcutaneously daily for 7 days
every 4 weeks. The overall response rate was 24 %. One
patient achieved partial response and 7 had clinical im-
provement, including 4 of 17 patients with splenomegaly
who had a reduction in spleen size [29]. The duration of
the response was 4 months. Odenike et al. reported the
results of a phase II trial with low-dose (0.3 mg/kg/d on
days 1–5 and days 8–12) decitabine in patients with
MF, in which 7 of 21 patients responded (1 complete
remission, 2 partial remissions, and 4 hematologic
improvements). The reduction of spleen size was not
reported [30].
Cladribine (2-chlorodeoxyadenosine; 2-CdA)
Cladribine (Ortho Biotech Products, L.P., Raritan, NJ,
USA) has been shown to have some palliative benefit
but there is little support for its use in spleen reduction
in MF patients. Although one study has reported a re-
sponse rate (defined as >50 % reduction in liver size, re-
duction of leukocytosis and thrombocytosis from
baseline, and rise of hemoglobin by > 20 g/L) of 64 %
after 1–2 treatment cycles, the response was mostly
among previously treated, splenectomized (11/14) MF
patients. Patients who were not splenectomized (3
patients) had poor response even after more treatment
cycles [31].
JAK2 inhibitors
JAKs are cytoplasmic kinases that play important roles
in normal hematopoiesis and proper immune function
[32]. Dysregulation of the JAK-STAT pathway is a highly
prevalent aberration in patients with MPNs, including
MF [33]. A number of alterations, such as excess cyto-
kines and increased JAK1 signaling, as well mutations in
JAK2 and mutations involving the thrombopoietin re-
ceptor (TPO-r or myeloproliferative leukemia, MPL,
oncogene) have also been implicated in the etiology and
symptomatology of MF, PV, and ET [33-36]. Although
JAK2V617F is the most common mutation associated
with these MPNs [3,35], it is not necessary for their de-
velopment [37-39]. Several JAK2 (or JAK1/JAK2) inhibi-
tors are currently in clinical trials for MF. Ruxolitinib
(formerly INCB018424; Incyte Corporation, Wilmington,
DE, USA) recently became the first FDA-approved drugfor the treatment of MF [40] and SAR302503 (formerly
TG101348; Sanofi, Paris, France) is in the phase 3 trial
for possible approval as therapy for MF. These 2 medica-
tions are described here in more detail.
Ruxolitinib is a potent and selective JAK1- and JAK2-
inhibitor (IC50 of 3.3 and 2.8 nmol/L, respectively, in
“naked” kinase assays in cell-free in vitro systems). It
demonstrates modest selectivity against Tyk2 (~ 6-fold)
and ≥ 130-fold selectivity against JAK3. Treatment with
ruxolitinib is associated with a dramatic decrease in cir-
culating levels of proinflammatory cytokines, IL-6, and
tumor necrosis factor (TNF)-α, which have been impli-
cated in the pathogenesis of MPNs [41].
The dosing regimen for ruxolitinib was established
during a phase I/II trial in 153 patients with primary
MF, post-PV MF, or post-ET MF [42]. Sixty-one of 140
patients (44 %) with splenomegaly at baseline had a re-
duction in spleen size ≥ 50 % by palpation within the first
3 months of therapy. Response was highest among
patients receiving 15 mg twice daily (bid; 52 %) and was
similar in patients with or without JAK2 mutation.
Ruxolitinib-treated patients also demonstrated reduc-
tions in spleen volume by MRI. The majority of patients
reported a > 50 % improvement in MF-related symp-
toms. Thrombocytopenia was the dose-limiting adverse
event. [42].
Results from 2 randomized phase III trials of ruxoliti-
nib in patients with intermediate-2 or high-risk MF have
recently been published. In the Controlled Myelofibrosis
Study with Oral JAK Inhibitor Treatment [COMFORT]-
I trial MF patients received oral ruxolitinib (n = 155) 15
or 20 mg bid (depending on baseline platelet count) or
placebo (n = 154). The primary endpoint, a ≥ 35 % reduc-
tion in spleen volume (by MRI or CT) at week 24, was
achieved in 41.9 % of ruxolitinib-treated patients vs.
0.7 % of placebo-treated patients (P < 0.001). At week 24,
significantly (P < 0.001) more patients in the ruxolitinib
group achieved a ≥ 50 % improvement in the Myelofibro-
sis Symptom Assessment Form (MFSAF) Total Symp-
tom Score (45.9 % vs. 5.3 % for placebo). At the time of
a planned safety update with 4 additional months of fol-
low-up, there was a significant survival advantage for
ruxolitinib over placebo (hazard ratio = 0.50; P = 0.04).
The most common nonhematologic adverse events that
occurred more often in the ruxolitinib group were ec-
chymosis, dizziness, and headache; these were mostly
grade 1 or 2. The most common adverse events were
hematologic. The rates of grade 3 and 4 anemia and
thrombocytopenia in the ruxolitinib group were 45 %
and 13 %, respectively, compared to 19 % and 1 %, re-
spectively in the placebo group [43].
In the COMFORT II study patients received ruxoliti-
nib (n = 146) or best available therapy (BAT; n = 73). At
week 48, 28.5 % of ruxolitinib-treated patients met the
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vs. 0 % in BAT group (P < 0.001). The most common
nonhematologic adverse events (all grades) were (ruxoli-
tinib vs. BAT) diarrhea (23 % vs. 12 %) and peripheral
edema (22 % vs. 26 %). In the ruxolitinib group, grade 3/
4 anemia and thrombocytopenia were reported in 42 %
and 8 % of patients, respectively, versus 31 % and 7 % re-
spectively in the BAT group [44]. In both studies, anemia
and thrombocytopenia were manageable and rarely led
to discontinuation.
SAR302503 is a selective and potent JAK2 inhibitor
profiled in 223 kinases and found to have an IC50 < 50
nM in 3 kinases— JAK2, FLT3, Ret [45]. It inhibits
growth of erythroid colonies in the presence of
JAK2V617F, MPL W515K, and JAK2 exon 12 mutations
[46] and is 35 and 334 times more selective for JAK2
compared with JAK1 and JAK3, respectively [45]. Parda-
nani et al. recently reported the results of a phase I dose
escalation study in which TG101348 was administered in
28-day cycles [47]. The study comprised 59 patients with
MF, post-PV MF, or post-ET MF with high/intermediate
risk disease and symptomatic splenomegaly unrespon-
sive to available therapy. Many patients with early sati-
ety, night sweats, fatigue, pruritus, and cough at baseline
reported rapid and durable improvement in these symp-
toms. Spleen response was seen within the first 2 cycles
of therapy. By 6 and 12 cycles 39 % and 47 % of patients,
respectively, had achieved a spleen response (IWG-MRT
criteria). No consistent change in plasma cytokine levels
was seen, indicating that this agent’s effect on the spleen
and the constitutional symptoms may be cytokine-inde-
pendent. The most common nonhematologic grade 3 or
4 adverse events included nausea (3.4 %), vomiting
(3.4 %), and diarrhea (10.2 %). Grade 3 or 4 anemia, neu-
tropenia, and thrombocytopenia was seen in 35.1 %,
10.2 %, and 23.7 % of patients, respectively.
Table 1 summarizes the clinical study findings for
these and several other agents currently in clinical trials
for MF (some published only in the abstract form).
Conclusions and future perspectives
MF is a severe, life-threatening, and intensely debilitat-
ing disease that has a significant and protracted detri-
mental effect on patients’ quality of life. Until recently
most treatments provided only palliative care with no
single treatment addressing all of the complications and
symptoms of the disorder. Although allogeneic stem cell
transplant offers the potential for cure, it is associated
with a high mortality rate, even using a reduced intensity
protocol, and thus is only appropriate for a limited
group of patients (e.g., younger, otherwise healthy
patients with high-risk MF). The discovery of a JAK2
mutation (JAK2V617F) and the dysregulated JAK-STAT
activity that is common in patients with MF, PV, and EThas led to the investigation of several agents that focus
on inhibition of JAK enzymatic activity. Clinical study
results to date indicate that the primary therapeutic ben-
efits of these therapies are a reduction in splenomegaly
and significant improvement in MF-related symptoms.
These improvements are generally seen within 1 to
2 months of initiating therapy and appear to be durable.
The adverse event profiles of the JAK inhibitors vary,
but the most common clinically significant adverse effect
is dose-related myelosuppression. As yet, no significant,
durable improvement in bone marrow fibrosis has been
reported with any of the therapies, and the effect of JAK
inhibitors and other novel agents under development on
the JAK2V617F allelic burden has been inconsistent.
Since no JAK2 inhibitor in clinical development so far
have been shown to be selective for JAK2V617F muta-
tion, and at the enzymatic level they inhibit both
mutated and wild-type JAK2 enzyme, it is not surprising
that the elimination of a JAK2 mutated clone in patients
on therapy has not been seen. Rather, JAK2 inhibitors
work equally well for MF patients with or without JAK2
mutation. It is plosible that mode of action of JAK2 inhi-
bitors is primarily anti-proliferative since JAK2 is
involved in essential hematopoiesis. Those JAK2 inhibi-
tors that also inhibit JAK1 (e.g. ruxolitinib) appear to
provide also anti-inflammatory effect, evidenced by the
significant reduction of inflammatory and other cyto-
kines in blood of patients on therapy. There remain a
number of unanswered questions concerning the exact
mechanism of action of these agents.
Although the JAK inhibitors are not curative, the
reductions in splenomegaly and systemic symptoms are
clinically significant and important to patients. Further
clinical development of ruxolitinib as well as the other
JAK inhibitors can be expected. Optimal timing of
treatment, dosage, and duration of therapy will become
better defined. For example, the use of JAK inhibitors
as first line therapy in patients with mild splenomegaly
to prevent spleen progression has to be investigated
since clinical experience with these agents so far has
been limited to patients with advanced MF and symp-
tomatic very enlarged spleen. Evaluation of the use of
JAK inhibitors in specific clinical situations is war-
ranted, for example, the use of JAK inhibitors in pre-
bone marrow transplant (BMT) period to allow for
BMT in better patients’ condition is mandatory as
BMT stays the only way to eliminate the disease and
potentially cure the patients. Similarly, their use in
patients with splenomegaly due to splanchnic vein
thrombosis in which the mechanism of splenomegaly is
probably different from that of typical myelofibrosis is
warranted as well. Furthermore, combination therapy,
likely based on a ruxolitinib backbone, may further im-
prove outcomes.
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available data indicate that JAK inhibitors are poised to
provide meaningful long-term benefits (possibly includ-
ing improved survival as seen in the COMFORT-I trial)
to patients with this serious, chronic, debilitating, and
potentially lethal disease. Currently we advocate the
use of ruxolitinib as the first option for the patients
with symptomatic, significant splenomegaly, that have
intermediate- and high-risk PMF or secondary MF.
There are select cases, however, where splenomegaly
can (and should) be controlled by either splenectomy
or splenic irradiation.
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